INTRODUCTION: The aim of this study was to elucidate the long-term outcomes in patients with choroidal melanoma who received episcleral brachytherapy with 125-I seeds; analyse cause-specific survival (CSS), metastasis-free survival (MFS), and local control; and establish the relationship between tumour size and metastases. METHODS: From May 2007 to February 2013, 88 patients classified according to the American Joint Committee on Cancer guidelines underwent ultrasound-guided episcleral brachytherapy with a total prescribed dose of 72.40 Gy to the apex. RESULTS: Among the included cases, 47.7 and 44.3% had a clinical tumour stage of T2 and T3, respectively. With a median follow-up of 84 (range 7-153) months, local control at 5 and 10 years was 100 and 95%, respectively. Among the 88 patients, 9 (10.2%) were enucleated after brachytherapy. Those with T1-T2 and T3-T4 disease had a 10-year CSS of 100 and 87.3%, respectively (p = 0.017). MFS at 5 and 10 years was 100% in those with T1-T2 disease and 92.1 and 83.1% in those with T3-T4, respectively (p = 0.016). Five patients had liver metastases, all of whom had T3-T4 disease. CONCLUSION: Ultrasound-guided episcleral brachytherapy with 125-I seeds yielded excellent local control for choroidal melanoma, with low complication rates and 90% eye preservation. Given the association between tumour stage and liver metastases, which remain the main cause of death, stricter control should be employed for T3-T4 tumours for the early detection and treatment of relapses.
INTRODUCTION: The aim of this study was to elucidate the long-term outcomes in patients with choroidal melanoma who received episcleral brachytherapy with 125-I seeds; analyse cause-specific survival (CSS), metastasis-free survival (MFS), and local control; and establish the relationship between tumour size and metastases. METHODS: From May 2007 to February 2013, 88 patients classified according to the American Joint Committee on Cancer guidelines underwent ultrasound-guided episcleral brachytherapy with a total prescribed dose of 72.40 Gy to the apex. RESULTS: Among the included cases, 47.7 and 44.3% had a clinical tumour stage of T2 and T3, respectively. With a median follow-up of 84 (range 7-153) months, local control at 5 and 10 years was 100 and 95%, respectively. Among the 88 patients, 9 (10.2%) were enucleated after brachytherapy. Those with T1-T2 and T3-T4 disease had a 10-year CSS of 100 and 87.3%, respectively (p = 0.017). MFS at 5 and 10 years was 100% in those with T1-T2 disease and 92.1 and 83.1% in those with T3-T4, respectively (p = 0.016). Five patients had liver metastases, all of whom had T3-T4 disease. CONCLUSION: Ultrasound-guided episcleral brachytherapy with 125-I seeds yielded excellent local control for choroidal melanoma, with low complication rates and 90% eye preservation. Given the association between tumour stage and liver metastases, which remain the main cause of death, stricter control should be employed for T3-T4 tumours for the early detection and treatment of relapses.
Authors: M A Astrahan; G Luxton; G Jozsef; T D Kampp; P E Liggett; M D Sapozink; Z Petrovich Journal: Int J Radiat Oncol Biol Phys Date: 1990-03 Impact factor: 7.038
Authors: Josep Maria Caminal; Josepa Ribes; Ramon Clèries; Nuria Ibáñez; Luis Arias; Josep Maria Piulats; Joan Pera; Cristina Gutierrez; Jorge Arruga Journal: Melanoma Res Date: 2012-06 Impact factor: 3.599
Authors: Subir Nag; Jeanne M Quivey; John D Earle; David Followill; James Fontanesi; Paul T Finger Journal: Int J Radiat Oncol Biol Phys Date: 2003-06-01 Impact factor: 7.038
Authors: Shahed N Badiyan; Rajesh C Rao; Anthony J Apicelli; Sahaja Acharya; Vivek Verma; Adam A Garsa; Todd DeWees; Christina K Speirs; Jose Garcia-Ramirez; Jacqueline Esthappan; Perry W Grigsby; J William Harbour Journal: Int J Radiat Oncol Biol Phys Date: 2014-01-22 Impact factor: 7.038
Authors: Chandrani Chattopadhyay; Dae Won Kim; Dan S Gombos; Junna Oba; Yong Qin; Michelle D Williams; Bita Esmaeli; Elizabeth A Grimm; Jennifer A Wargo; Scott E Woodman; Sapna P Patel Journal: Cancer Date: 2016-03-15 Impact factor: 6.860
Authors: Daniel Lorenzo; María Ochoa; Josep Maria Piulats; Cristina Gutiérrez; Luis Arias; Jaume Català; María Grau; Judith Peñafiel; Estefanía Cobos; Pere Garcia-Bru; Marcos Javier Rubio; Noel Padrón-Pérez; Bruno Dias; Joan Pera; Josep Maria Caminal Journal: Cancer Res Treat Date: 2017-12-04 Impact factor: 4.679